Normalization of Glycemia in Diabetics During Meals with Insulin and Glucagon Delivery by the Artificial Pancreas

An extracorporeal “closed-loop” system has been employed to maintain glycemia in the normal range during consumption of meals in nine insulin-treated diabetics. This artificial pancreas system incorporated continuous blopd glucose monitoring (0.05 ml. per minute, delay time 90 seconds), a computer programed to respond to glycemia, and a hormone delivery system. Intravenous insulin delivery rates were determined by control parameters responsive to both glucose concentration and its rate of change. Because insulin-dependent diabetics often defend themselves poorly against hypoglycemie (in some cases due to inadequate glucagon responses), the instrument was also programed for exogenous glucagon delivery. A priori selection of ideal parameters for insulin and glucagon delivery for each individual is not yet possible. Con sequently, when the parameters were used for the first time on each subject, they were varied over a reasonable range. This approach resulted in a corresponding variety of glycemie responses, the average of which characterized a set of initial parameters that is generally applicable. Appropriate control parameters are presented that successfully prevented hypoglycemie. Glucagon delivery directly related to glycemia appeared sufficient for this purpose, thus obviating the need for dextrose administration. This system provides a technique for complete normalization of blood glucose concentration in the types of diabetics tested, during both fed and interprandial periods. It has yielded insights essential to the development of more sophisticated future devices.

[1]  J. Planques,et al.  [Normal man]. , 1953, Toulouse medical.

[2]  R. Unger,et al.  Measurements of endogenous glucagon in plasma and the influence of blood glucose concentration upon its secretion. , 1962, The Journal of clinical investigation.

[3]  W. F. Taylor,et al.  Mean Amplitude of Glycemic Excursions, a Measure of Diabetic Instability , 1970, Diabetes.

[4]  A. P. Hansen Normalization of growth hormone hyperresponse to exercise in juvenile diabetics after "normalization" of blood sugar. , 1971, The Journal of clinical investigation.

[5]  M. Vranic,et al.  Effect of glucagon on glucose turnover and plasma free fatty acids in depancreatized dogs maintained on matched insulin infusions. , 1972, Canadian journal of physiology and pharmacology.

[6]  J. Gerich,et al.  Lack of Glucagon Response to Hypoglycemia in Diabetes: Evidence for an Intrinsic Pancreatic Alpha Cell Defect , 1973, Science.

[7]  S. Genuth Plasma insulin and glucose profiles in normal, obese, and diabetic persons. , 1973, Annals of internal medicine.

[8]  J. Hiebert,et al.  Progress Towards an Implantable Glucose Sensor and an Artificial Beta Cell , 1973 .

[9]  G. Slama,et al.  One to Five Days of Continuous Intravenous Insulin Infusion on Seven Diabetic Patients , 1974, Diabetes.

[10]  J. Gerich,et al.  Characterization of the glucagon response to hypoglycemia in man. , 1974, The Journal of clinical endocrinology and metabolism.

[11]  S. B. Lewis,et al.  Effects of glucagon on lipolysis and ketogenesis in normal and diabetic men. , 1974, The Journal of clinical investigation.

[12]  G. Weir,et al.  Glucagon secretion from the perfused rat pancreas. Studies with glucose and catecholamines. , 1974, The Journal of clinical investigation.

[13]  W Zingg,et al.  Clinical Control of Diabetes by the Artificial Pancreas , 1974, Diabetes.

[14]  E. Tsalikian,et al.  Normalization of fasting hyperglucagonemia and excessive glucagon responses to intravenous arginine in human diabetes mellitus by prolonged infusion of insulin. , 1975, The Journal of clinical endocrinology and metabolism.

[15]  J. Palmer,et al.  Arginine-stimulated Acute Phase of Insulin and Glucagon Secretion: I. In Normal Man , 1975, Diabetes.

[16]  E. Pfeiffer,et al.  Antidiabetic Action of Somatostatin–Assessed by the Artificial Pancreas , 1975, Diabetes.

[17]  W. Zingg,et al.  An all-plastic double-lumen catheter for continuous blood sampling. , 1975, Medical instrumentation.

[18]  R E Gander,et al.  Comparison of Peripheral and Portal Routes of Insulin Infusion by a Computer-controlled Insulin Infusion System (Artificial Endocrine Pancreas) , 1976, Diabetes.

[19]  C. Botz An improved control algorithm for an artificial beta-cell. , 1976, IEEE transactions on bio-medical engineering.

[20]  R. D. Schultz,et al.  Continuous Extracorporeal Monitoring of Animal Blood Using the Glucose Electrode , 1976, Diabetes.

[21]  R. Sherwin,et al.  Hyperglucagonemia and blood glucose regulation in normal, obese and diabetic subjects. , 1976, The New England journal of medicine.

[22]  B. Zinman,et al.  The metabolic response to moderate exercise in diabetic man receiving intravenous and subcutaneous insulin. , 1977, The Journal of clinical endocrinology and metabolism.

[23]  A. Albisser,et al.  An improved technique for the rapid continuous measurement of whole blood glucose, suitable for clinical application in an artificial endocrine pancreas. , 1977, Medical progress through technology.

[24]  H. Mehnert,et al.  Glucose homeostasis under continuous intravenous insulin therapy in diabetics. , 1977, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.